# nature portfolio

Corresponding author(s): Peter Moffett

Last updated by author(s): Jan 22, 2023

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

#### **Statistics**

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a	Cor	firmed			
	X	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
×		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
	X	A description of all covariates tested			
	x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
×		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.			
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated			
	•	Our web collection on statistics for biologists contains articles on many of the points above.			

## Software and code

Policy information about <u>availability of computer code</u>					
Data collection	N/A				
Data analysis	N/A				

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The source data analyzed for Figs. 1-6, Supplementary Figs. 1-7 are provided as a Source Data file.

### Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Statistical methods were not used to predetermine necessary sample size. Rather, efforts were made to ensure large replicate numbers per experiment (usually n>18 per experiment), and replicate experiments were performed. Experiments were repeated at least three times.
Data exclusions	N/A
Replication	Experiments were performed at least three independent times to confirm reproducibility. All findings from replicate experiments were consistent and confirmed.
Randomization	Each replicate pot of each condition of the experiment was distributed at random into the growth chamber.
Blinding	Experiments were conducted in non-blinded and blinded ways by two experimenters to confirm reproducibility and reduce biais.

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

#### Materials & experimental systems

n/a	Involved in the study
×	Antibodies
×	Eukaryotic cell lines
×	Palaeontology and archaeology
	X Animals and other organisms
×	Clinical data
×	Dual use research of concern

#### Methods

n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging

#### Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals	N/A
Wild animals	N/A

Reporting on sex	N/A
Field-collected samples	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.